Mirum Pharmaceuticals Inc (MIRM) Noticias

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on December 10, 2024, the Compensation Committee of Mirum’s Board of Directors...

Form 4 - Statement of changes in beneficial ownership of securities

Mirum Pharmaceuticals to Showcase Data from its LIVMARLI and Volixibat Clinical Programs at AASLD’s The Liver Meeting

- Late-breaker presentation to feature data from VANTAGE study evaluating volixibat in primary biliary cholangitis Mirum Pharmaceuticals, Inc...

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Mirum Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Third quarter global net product sales of $90.3 million; 2024 guidance increased to $330 - 335 million Volixibat granted breakthrough therapy...

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on November 8, 2024, the Compensation Committee of Mirum’s Board of Directors...

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and...

Mirum Pharmaceuticals to Announce Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report third quarter 2024 financial results on November 12, 2024. Mirum...

Mirum Pharmaceuticals to Showcase LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced its participation in the North American Society for Pediatric Gastroenterology...

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that on October 10, 2024, the Compensation Committee of Mirum’s Board of Directors...

Volixibat Granted Breakthrough Therapy Designation for Cholestatic Pruritus in Primary Biliary Cholangitis

- Designation based on positive interim analysis of Phase 2b VANTAGE study Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that the...

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that on September 10, 2024, the Compensation Committee of Mirum’s Board of Directors...

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and...